Metsera reported positive results from a pair of Phase IIb studies for its ultra-long-acting GLP-1 receptor agonist MET-097i on Monday, one week after Pfizer agreed to acquire the obesity-focused biotech for up to $7.3 billion.
Topline data from the VESPER-1 trial and interim tolerability results from VESPER-3 support initiation of Phase III testing in late 2025, Metsera said. The trials assessed MET-097i in overweight or obese populations without type 2 diabetes.
In VESPER-1, MET-097i was evaluated in 239 participants at weekly doses of 0.4 mg to 1.2 mg over 28 weeks without titration, with an ongoing extension study exploring less frequent dosing schedules. Metsera said body-weight loss was dose-dependent, reaching a placebo-subtracted mean of 14.1% with the 1.2 mg dose (n=54), while individual participants saw reductions of up to 26.5%.
An exploratory analysis at week 36 of the VESPER-1 extension study showed "substantial continued weight loss," indicating that participants had not yet reached a plateau.
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.